Identification of CNS-homing peptides for therapeutic use in multiple sclerosis

鉴定用于治疗多发性硬化症的中枢神经系统归巢肽

• 批准号: 8638421
• 负责人: KAMAL D MOUDGIL
• 金额: $ 23.03万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-30 至 2015-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8638421
• 关键词: Address; Adjuvant Arthritis; Adverse effects; Adverse reactions; Alanine; Animal Model; Antibodies; Antigens; Area; Arginine; Arthritis; Asparagine; Aspartic Acid; Autoantigens; Autoimmune Diseases; Autoimmune Process; Autoimmunity; Bacteriophages; Binding; Blood - brain barrier anatomy; Blood Circulation; Blood Vessels; Brain; Cells; Characteristics; Chronic; Clinical; Code; Collaborations; Detection; Development; Disease; Drug Delivery Systems; Drug Targeting; Encapsulated; Experimental Autoimmune Encephalomyelitis; Glutamine; Glycine; Heterogeneity; Home environment; Homing; Human; Immune; Individual; Inflammation; Inflammation Mediators; Institutes; Integrins; Interferons; Joints; Leukocyte Trafficking; Libraries; Ligands; Liposomes; Lysine; Methodology; Methods; Mitoxantrone; Modeling; Multiple Sclerosis; Mus; Myelin Basic Proteins; Neuraxis; Normal tissue morphology; Organ; Paralysed; Pathogenesis; Pathology; Peptide Phage Display Library; Peptides; Phage Display; Pharmaceutical Preparations; Physiological; Play; Process; Proteins; Proteolipids; Publishing; RGD (sequence); Rattus; Reporting; Research Personnel; Role; SJL Mouse; Site; Spinal Cord; Study models; System; T-Lymphocyte; Techniques; Therapeutic; Therapeutic Agents; Therapeutic Index; Therapeutic Uses; Tissues; Toxic effect; Translational Research; Tysabri; Vascular Endothelial Cell; Vascular Endothelium; Work; angiogenesis; autoreactive T cell; base; copolymer 1; design; disability; in vivo; innovation; insight; lymph nodes; migration; molecular marker; mouse myelin oligodendrocyte glycoprotein; natalizumab; neoplastic cell; novel; novel strategies; novel therapeutic intervention; oligodendrocyte-myelin glycoprotein; public health relevance; receptor binding; screening; trafficking; treatment strategy

PROJECT SUMMARY Multiple sclerosis (MS) is a chronic debilitating autoimmune disease involving inflammation and damage to the central nervous system (CNS). A variety of autoantigens, including myelin oligodendrocyte glycoprotein (MOG), proteolipid protein (PLP), and myelin basic protein (MBP) have been implicated in the pathogenesis of MS. The T cells reactive against these antigens access the CNS through the blood-brain barrier and cause inflammation and tissue damage. Two of the main challenges for researchers working in the field of MS are - 1) to define the underlying mechanisms that render the CNS highly prone to an autoimmune attack, and 2) to devise novel ways to direct the orally-administered or injected drugs primarily into the CNS to enhance their efficacy while minimizing adverse effects. We hypothesize that the vascular endothelium of the CNS is characterized by unique molecular markers that facilitate both selective migration of the pathogenic T cells into the target organ (the CNS) as well as cellular interaction with the inducers/mediators of inflammation and tissue damage. In collaboration with Dr. Erkki Ruoslahti (Sanford-Burnham Institute at La Jolla, CA), we recently completed and published (PNAS 2011, 108: 12857) study of the synovial vasculature in the rat adjuvant arthritis model. The objective of that study was to identify unique joint-specific vascular markers using an innovative approach of in vivo enrichment of clones from a phage peptide-display library. The advantage of the phage system for detection of tissue-specific markers is that there is no a priori bias in predicting the ligand in the vascular endothelium. In addition, unlike antibodies, the phage-displayed peptides interact with the functional domain of the target molecule. This approach has been pioneered by Dr. Ruoslahti, who has developed the concept of vascular 'address molecules' or 'zip codes'. His group and other investigators have examined several organs in this regard except the inflamed CNS. We hypothesize that the vascular endothelium of the brain and the spinal cord in EAE is characterized by unique molecular markers, and that the targeting of drugs via one or more of these markers would downregulate inflammation and tissue damage in the CNS without undue adverse reactions or systemic toxicity. The aims of our study based on MOG-EAE and PLP-EAE models (and in collaboration with Dr. Ruoslahti, and EAE experts- Drs. Scott and Lees) are as follows: Aim 1, to identify unique 'address molecules' for vascular endothelium of the inflamed CNS in mice with EAE using the in vivo screening of phage peptide-display library method. Aim 2, to use CNS-homing peptides for vasculature-targeted drug delivery into sites of CNS inflammation and tissue damage. We believe that the results of this study would advance our understanding of the pathogenesis of EAE/MS, and pave the way for designing novel peptide-directed therapeutics for MS through translational research. .

项目总结 多发性硬化症(MS)是一种慢性衰弱的自身免疫性疾病，涉及炎症和对 中枢神经系统(CNS)。多种自身抗原，包括髓鞘少突胶质细胞糖蛋白 (MOG)、蛋白脂蛋白(PLP)和髓鞘碱性蛋白(MBP)参与了糖尿病的发病机制。 对这些抗原起反应的T细胞通过血脑屏障进入中枢神经系统，并引起 炎症和组织损伤。多发性硬化症领域的研究人员面临的两个主要挑战是- 1)定义使CNS高度容易受到自身免疫攻击的潜在机制，以及2) 设计新的方法将口服或注射的药物主要引导到中枢神经系统，以增强其 有效的同时将不良反应降至最低。我们假设中枢神经系统的血管内皮细胞是 以独特的分子标记为特征的，促进致病T细胞选择性迁移到 靶器官(中枢神经系统)以及细胞与炎症和炎性介质的相互作用。 组织损伤。在与Erkki Ruola hti博士(加利福尼亚州拉霍亚的Sanford-Burnham研究所)的合作下，我们 最近完成并发表的(PNAS2011,108：12857)大鼠滑膜血管系统的研究 佐剂性关节炎模型。该研究目的是确定独特的关节特异性血管标志物 一种从噬菌体多肽展示文库中体内富集克隆的创新方法。的优势 用于检测组织特异性标记的噬菌体系统是在预测配基时没有先验偏差 在血管内皮细胞。此外，与抗体不同的是，噬菌体展示的多肽与 靶分子的功能结构域。这种方法是鲁斯拉赫蒂博士率先提出的，他已经 提出了血管“地址分子”或“邮政编码”的概念。他的团队和其他调查人员已经 检查了这方面的几个器官，除了发炎的中枢神经系统。我们假设血管 EAE患者的脑和脊髓内皮细胞具有独特的分子标记特征，并且 通过这些标记物中的一个或多个靶向药物将下调炎症和组织损伤 中枢神经系统无不当不良反应或全身毒性。我们的研究目标是基于MOG-EAE和 PLP-EAE模型(并与Ruola hti博士以及EAE专家Scott和Lees博士合作)是AS 目的1、确定炎症小鼠中枢神经系统血管内皮细胞独特的“地址分子” 用噬菌体展示文库方法对EAE进行体内筛选。目标2，使用中枢神经系统寻的 用于血管系统靶向药物输送到中枢神经系统炎症和组织损伤部位的多肽。我们相信 本研究的结果将促进我们对EAE/MS发病机制的认识，并为 通过翻译研究设计多发性硬化症的新型多肽导向疗法的途径。 。